Targeted protein degradation is changing how drug discovery teams think about disease biology. For many years, small molecule programs were built around inhibition. A compound was expected to bind a disease-relevant protein and block its activity. That logic still works for many targets. But it is not enough for proteins that lack clear binding pockets, act mainly as scaffolds, or drive disease through non-enzymatic functions. This is where targeted protein degradation has become important. It asks a different question: instead of only blocking a protein, can the cell be directed to remove it?
Why targeted protein degradation matters now
The interest in targeted protein degradation comes from a real limitation in conventional drug discovery. A large part of the proteome has remained difficult to drug with classical inhibitors. These include transcription factors, scaffolding proteins, mutant proteins, and proteins involved in complex regulatory networks. Many are linked to cancer, immunology, inflammation, neurodegeneration, and rare diseases.
Degraders use the cell’s protein disposal systems, mainly the ubiquitin proteasome system, to bring a protein of interest close to an E3 ligase. The target protein is then marked for degradation. This event-driven mechanism can sometimes give a stronger and more sustained biological effect than occupancy-driven inhibition.
The promise is serious, but it should not be oversold. A degrader is not automatically better than an inhibitor. It must show selective degradation, cellular activity, useful exposure, manageable safety, and a development path that can survive formulation and scale-up pressures.
Undruggable targets and the new discovery logic
Moving beyond target binding alone
The phrase undruggable targets is often used too loosely. In practical terms, it refers to targets that are hard to modulate using conventional small molecules because they lack suitable binding pockets or because inhibition does not adequately affect their disease-driving role. Targeted protein degradation brings a new logic to these targets. Binding is still required, but binding alone is not the full objective. The degrader must induce proximity, form a productive ternary complex, trigger ubiquitination, and deliver measurable degradation inside the cell.
This changes the discovery cascade. A program cannot rely only on affinity or biochemical potency. It needs cellular degradation data, kinetics, proteomics, pathway readouts, and early developability checks. A weak binder may become useful if it drives efficient degradation. A strong binder may fail if it does not form a productive complex. Old rules help, but they do not decide the program.
PROTAC drug discovery and molecular glues
PROTAC drug discovery has become one of the best-known areas within targeted protein degradation. PROTACs are heterobifunctional molecules, with one ligand binding the protein of interest, another ligand binding an E3 ligase, and a linker connecting them. Their design gives medicinal chemists several variables to work with, including E3 ligase selection, linker length, exit vector, polarity, permeability, and metabolic stability.
Molecular glues are generally smaller molecules that stabilize or induce interaction between a target protein and an E3 ligase. They may offer better drug-like properties in some cases, but their discovery can be less predictable because suitable starting points are harder to rationally design.
Both approaches are expanding the reach of tpd drug development. They also bring practical difficulty. PROTACs often sit outside conventional Rule of Five space. Molecular glues may look simpler on paper, but finding selectivity and the right degradation biology is not simple.
Protein degradation assays as decision tools
Assay design decides the quality of the program
Protein degradation assays are not supporting experiments in TPD. They are central decision tools. A degrader program needs assays that can separate binding, target engagement, degradation, pathway modulation, and downstream phenotype. Western blotting, capillary western methods, HiBiT or NanoLuc tag-based systems, immunofluorescence, flow-based readouts, and mass spectrometry-based proteomics can all contribute, depending on the target and stage of the program.
The critical point is assay fit. A tag-based assay can help improve throughput, but it may not fully represent endogenous biology. Endogenous protein detection is closer to physiological relevance, but it may be slower and harder to scale. A cell viability readout alone is weak evidence unless it is connected to target degradation and mechanism.
From degradation to developability
Good protein degradation assays should also support chemistry decisions. The data should explain whether changes in linker length, E3 ligand, stereochemistry, or physicochemical properties improve degradation, potency, selectivity, and exposure. The best cascades connect biology with DMPK, safety, and formulation thinking early. Waiting until late discovery to face permeability, solubility, metabolic stability, or bioavailability issues is costly, especially in PROTAC programs.
This is why TPD programs need integrated review points. A molecule that looks strong in one cell line may fail across disease-relevant models. A degrader with excellent DC50 may still have poor Dmax, slow kinetics, or inadequate selectivity. A compound may degrade the target but still not translate into a durable pharmacodynamic effect.
TPD drug development needs integrated capability
Chemistry, biology, DMPK, and analytics must move together
TPD drug development is not a linear handover from chemistry to biology to DMPK. It works better when these functions move in parallel. Medicinal chemistry must understand the degradation hypothesis. Biology must interpret whether the observed effect is target-linked. DMPK must flag exposure and metabolism risks early. Analytical and bioanalytical teams must support reliable quantitation, metabolite understanding, and translational readouts.
This discipline is important for novel modalities, where the standard playbook may not be enough. The challenge is not only to make a degrader. The challenge is to make a degrader that behaves like a drug candidate.
Getting on the frontline
Being on the frontline of targeted protein degradation means entering the program before the easy claims are made. It means testing whether the target is suitable for degradation, whether the disease context justifies the approach, whether the assay system is reliable, and whether chemistry can be optimized without losing developability.
For sponsors, the value lies in decisions made early: which target to pursue, which E3 ligase to explore, which assay cascade to trust, which chemistry series to stop, and when to move from hit finding to candidate-quality optimization. For CRDMO-led programs, continuity matters. Fragmented execution can create attractive data packages that do not hold together when the molecule enters deeper development.
Concluding thoughts
Targeted protein degradation has reached a stage where the field needs fewer broad promises and more disciplined execution. The opportunity is real. It can address difficult biology, including some undruggable targets, and can reshape how drug discovery approaches novel modalities. But progress will depend on clear target logic, robust protein degradation assays, integrated PROTAC drug discovery, and development thinking that starts early. That is the real frontline.
As targeted protein degradation moves toward broader therapeutic impact, integrated discovery capabilities become critical to translating promise into progress. Syngene supports this journey by bringing together biology, chemistry, and development insight across novel modality programs.